{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:21:46Z","timestamp":1793744506687,"version":"4.6.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.tjpad.2025.100327","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:24:24Z","timestamp":1761528264000},"page":"100327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Harnessing combination therapy: Current treatments, recent advancements, and future directions in Alzheimer's disease"],"prefix":"10.1016","volume":"12","author":[{"given":"Howard M","family":"Fillit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Touchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura K","family":"Nisenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0176-9184","authenticated-orcid":false,"given":"Aaron H","family":"Burstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.tjpad.2025.100327_bib0001","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1212\/WNL.0000000000006745","article-title":"Translating the biology of aging into novel therapeutics for Alzheimer disease","volume":"92","author":"Hara","year":"2019","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100327_bib0002","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.cell.2014.10.039","article-title":"Geroscience: linking aging to chronic disease","volume":"159","author":"Kennedy","year":"2014","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100327_bib0003","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra2301292","article-title":"Frailty in older adults","volume":"391","author":"Kim","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100327_bib0004","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1186\/s12889-025-22378-z","article-title":"Global burden of Alzheimer's disease and other dementias in adults aged 65 years and over, and health inequality related to SDI, 1990-2021: analysis of data from GBD 2021","volume":"25","author":"Liu","year":"2025","journal-title":"BMC Public Health"},{"key":"10.1016\/j.tjpad.2025.100327_bib0005","article-title":"older population grew from 2010 to 2020 at fastest rate since 1880 to 1890","year":"2025","journal-title":"U S Census Bur"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100327_bib0007","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41392-022-01251-0","article-title":"Aging and aging-related diseases: from molecular mechanisms to interventions and treatments","volume":"7","author":"Guo","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100327_bib0008","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.cger.2013.07.002","article-title":"Normal cognitive aging","volume":"29","author":"Harada","year":"2013","journal-title":"Clin Geriatr Med"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100327_bib0009","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/hbm.21374","article-title":"Brain structural trajectories over the adult lifespan","volume":"33","author":"Ziegler","year":"2012","journal-title":"Hum Brain Mapp"},{"issue":"24","key":"10.1016\/j.tjpad.2025.100327_bib0010","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1212\/WNL.0000000000003425","article-title":"Amyloid deposition in younger adults is linked to episodic memory performance","volume":"87","author":"Bischof","year":"2016","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100327_bib0011","doi-asserted-by":"crossref","DOI":"10.1172\/JCI158453","article-title":"Biological aging processes underlying cognitive decline and neurodegenerative disease","volume":"132","author":"Gonzales","year":"2022","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100327_bib0012","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1037\/pag0000288","article-title":"Trajectories of normal cognitive aging","volume":"34","author":"Salthouse","year":"2019","journal-title":"Psychol Aging"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100327_bib0013","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3233\/JAD-160612","article-title":"Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer's disease neurons","volume":"57","author":"Rajmohan","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100327_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2024.100001","article-title":"Key considerations for combination therapy in Alzheimer's clinical trials: perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation","volume":"12","author":"Cummings","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"7955","key":"10.1016\/j.tjpad.2025.100327_bib0015","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/d41586-023-00954-w","article-title":"Conquering Alzheimer's: a look at the therapies of the future","volume":"616","author":"Abbott","year":"2023","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100327_bib0016","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40263-024-01103-1","article-title":"Alzheimer's disease: combination therapies and clinical trials for combination therapy development","volume":"38","author":"Cummings","year":"2024","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100327_bib0017","article-title":"Alzheimer\u2019s disease drug development pipeline: 2024","volume":"10","author":"Cummings","year":"2024","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.tjpad.2025.100327_bib0046","article-title":"Senolytic therapy to modulate the progression of Alzheimer's disease (SToMP-AD) study (SToMP-AD)","year":"2025","journal-title":"Updated"},{"key":"10.1016\/j.tjpad.2025.100327_bib0047","article-title":"A study of E2814 with concurrent lecanemab treatment in participants with early Alzheimer's disease","year":"2025","journal-title":"Updated"},{"key":"10.1016\/j.tjpad.2025.100327_bib0048","article-title":"Metformin and FINGER intervention to prevent cognitive impairment and disability in older adults at risk for dementia (MET-FINGER)","year":"2025","journal-title":"Updated"},{"key":"10.1016\/j.tjpad.2025.100327_bib0049","article-title":"A study to assess efficacy and safety of KarXT for the treatment of psychosis associated with Azheimer's disease (ADEPT-1)","year":"2025","journal-title":"Updated"},{"key":"10.1016\/j.tjpad.2025.100327_bib0050","article-title":"Randomized I\/\u200bII phase study of ALZT-OP1 combination therapy in Alzheimer's disease and normal healthy volunteers","year":"2025","journal-title":"Updated"},{"key":"10.1016\/j.tjpad.2025.100327_bib0051","article-title":"Masitinib in patients with mild to moderate Alzheimer's disease","year":"2025","journal-title":"Updated"},{"key":"10.1016\/j.tjpad.2025.100327_bib0052","article-title":"Study to assess the safety and biological activity of AMX0035 for the treatment of Alzheimer's disease (PEGASUS)","year":"2025","journal-title":"Updated"},{"key":"10.1016\/j.tjpad.2025.100327_bib0053","article-title":"A study of donanemab, RG6289, or the combination of donanemab and RG6289 in presenilin 1 (PSEN1) E280A mutation carriers for the treatment of autosomal-dominant Alzheimer's disease","year":"2025","journal-title":"Updated"},{"key":"10.1016\/j.tjpad.2025.100327_bib0054","article-title":"Alzheimer's tau platform: master protocol (ATP)","year":"2025","journal-title":"Updated"},{"issue":"22","key":"10.1016\/j.tjpad.2025.100327_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213954","article-title":"Alzheimer's disease: treatment strategies and their limitations","volume":"23","author":"Passeri","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100327_bib0019","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.3390\/ijms21093272","article-title":"Combination drug therapy for the management of Alzheimer\u2019s disease","volume":"21","author":"Kabir","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tjpad.2025.100327_bib0020","unstructured":"Leqembi. Prescribing Information. Eisai Inc. And Biogen. 2025."},{"key":"10.1016\/j.tjpad.2025.100327_bib0021","series-title":"Prescribing Information","year":"2024"},{"key":"10.1016\/j.tjpad.2025.100327_bib0022","series-title":"Update on regulatory review of lecanemab for early Alzheimer's disease by the European Commission","year":"2025"},{"key":"10.1016\/j.tjpad.2025.100327_bib0023","article-title":"Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease","year":"2025","journal-title":"Press release"},{"key":"10.1016\/j.tjpad.2025.100327_bib0024","series-title":"Nanocarriers for the Delivery of Combination Drugs","first-page":"1","article-title":"Combination therapy: past, present, and future","author":"Iqubal","year":"2021"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100327_bib0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100327_bib0026","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100327_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/jnr.70046","article-title":"Alzheimer's disease and frontotemporal dementia: a review of pathophysiology and therapeutic approaches","volume":"103","author":"Kelliny","year":"2025","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.tjpad.2025.100327_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1390248","article-title":"Editorial: benefits and risks of drug combination therapy for chronic metabolic diseases","volume":"15","author":"Qiu","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.tjpad.2025.100327_bib0029","article-title":"Prescribing information","year":"2025","journal-title":"Novo Nord A\/S"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100327_bib0030","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","article-title":"evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease","volume":"17","author":"Cummings","year":"2025","journal-title":"Alzheimers Res Ther"},{"issue":"S9","key":"10.1016\/j.tjpad.2025.100327_bib0031","doi-asserted-by":"crossref","DOI":"10.1002\/alz.057848","article-title":"Evaluation of liraglutide in the treatment of Alzheimer's disease","volume":"17","author":"Edison","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100327_bib0032","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13195-024-01482-z","article-title":"Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer\u2019s disease: a randomized, controlled clinical trial","volume":"16","author":"Ornish","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100327_bib0033","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13195-023-01355-x","article-title":"A multimodal precision-prevention approach combining lifestyle intervention with metformin repurposing to prevent cognitive impairment and disability: the MET-FINGER randomised controlled trial protocol","volume":"16","author":"Barbera","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"21","key":"10.1016\/j.tjpad.2025.100327_bib0034","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252111338","article-title":"Future therapeutic strategies for Alzheimer\u2019s disease: focus on behavioral and psychological symptoms","volume":"25","author":"Kwon","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tjpad.2025.100327_bib0035","doi-asserted-by":"crossref","first-page":"100328","DOI":"10.1016\/j.tjpad.2025.100328","article-title":"Alzheimer combination therapies: overview and scenarios","author":"Cummings","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100327_bib0036","doi-asserted-by":"crossref","first-page":"100359","DOI":"10.1016\/j.tjpad.2025.100359","article-title":"Add-on combination therapy with monoclonal antibodies: implications for drug development","author":"Cummings","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100327_bib0037","doi-asserted-by":"crossref","first-page":"100366","DOI":"10.1016\/j.tjpad.2025.100366","article-title":"The role for artificial intelligence in identifying combination therapies for Alzheimer\u2019s disease","author":"Cheng","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100327_bib0038","doi-asserted-by":"crossref","first-page":"100391","DOI":"10.1016\/j.tjpad.2025.100391","article-title":"The impact of recent approvals on future Alzheimer\u2019s disease clinical development: statistical considerations for combination trials","author":"Dickson","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100327_bib0039","doi-asserted-by":"crossref","first-page":"100392","DOI":"10.1016\/j.tjpad.2025.100392","article-title":"Statistical innovations in clinical trial design with a focus on drug combinations, factorials, and other multiple therapy issues","author":"Berry","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100327_bib0041","first-page":"100367","article-title":"Risk reduction and precision prevention across the Alzheimer\u2019s disease continuum: a systematic review of clinical trials combining multidomain lifestyle interventions and pharmacological or nutraceutical approaches","author":"Barbera","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100327_bib0042","doi-asserted-by":"crossref","first-page":"100329","DOI":"10.1016\/j.tjpad.2025.100329","article-title":"Combination repurposed treatments for Alzheimer\u2019s Disease","author":"Ballard","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100327_bib0043","doi-asserted-by":"crossref","first-page":"393","DOI":"10.14283\/jpad.2022.48","article-title":"The future of AD clinical trials with the advent of anti-amyloid therapies: an CTAD task force report","volume":"3","author":"Delrieu","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"S6","key":"10.1016\/j.tjpad.2025.100327_bib0044","doi-asserted-by":"crossref","DOI":"10.1002\/alz.085111","article-title":"The Alzheimer\u2019s Tau Platform (ATP): a phase 2, combination amyloid and tau therapy clinical trial for early AD","volume":"20","author":"Boxer","year":"2025","journal-title":"Alzheimers Dement"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725002705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725002705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:13:05Z","timestamp":1784232785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725002705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2274580725002705"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100327","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing combination therapy: Current treatments, recent advancements, and future directions in Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100327","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100327"}}